Business
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
BOSTON, October 22, 2025--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF
About this update from Puretech Health Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":7367,"height":2362,"url":"https://media.zenfs.com/en/business-wire.com/040094997ad9897d6947feea223b91fa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dNncFUimEa7T8YCPqSg9Cg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/040094997ad9897d6947feea223b91fa","width":960,"height":308},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/txDt02fZF28yTR8kUF7QeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NzA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/040094997ad9897d6947feea223b91fa","width":1200,"height":385}},"lazy":false},{"type":"text","content":"Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone’s differentiated profile and potential to address unmet needs across age groups","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, October 22, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a hub-and-spoke biotherapeutics company dedicated to giving life to science and transforming innovation into value, today announced the presentation of new analyses from the Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100) for the treatment of idiopathic pulmonary fibrosis (IPF). The data show that the favorable safety and efficacy profile of deupirfenidone was consistent across age groups, including in patients aged 75 years and older. These findings, presented at the American College of Chest Physicians (CHEST) 2025 Annual Meeting, suggest that deupirfenidone may address a key gap in the treatment of IPF, as older patients have historically been less likely to be treated, largely due to tolerability challenges.1,2 These data further reinforce deupirfenidone’s differentiated profile and support its potential to meaningfully improve care for this vulnerable population.","length":1027,"tagName":"p"},{"type":"text","content":""These data are a welcome indication that age does not necessarily translate to a poorer treatment experience in IPF, which is generally a disease of older people," said Tejaswini Kulkarni, MD, MPH, Associate Professor of Pulmonary, Allergy and Critical Care Medicine at the University of Alabama at Birmingham...